Blueprint Medicines (BPMC) Misses Q2 EPS by 7c

Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($0.86), $0.07 worse than the analyst estimate of ($0.79).

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• HP Inc. projects mid-single-digit PC market decline in 2027
• Super Micro Computer rises on AI server market optimism